These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 34815418)

  • 21. UBE3A reinstatement as a disease-modifying therapy for Angelman syndrome.
    Elgersma Y; Sonzogni M
    Dev Med Child Neurol; 2021 Jul; 63(7):802-807. PubMed ID: 33543479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Drosophila model for Angelman syndrome.
    Wu Y; Bolduc FV; Bell K; Tully T; Fang Y; Sehgal A; Fischer JA
    Proc Natl Acad Sci U S A; 2008 Aug; 105(34):12399-404. PubMed ID: 18701717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypersociability in the Angelman syndrome mouse model.
    Stoppel DC; Anderson MP
    Exp Neurol; 2017 Jul; 293():137-143. PubMed ID: 28411125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angelman syndrome-associated point mutations in the Zn
    Kühnle S; Martínez-Noël G; Leclere F; Hayes SD; Harper JW; Howley PM
    J Biol Chem; 2018 Nov; 293(47):18387-18399. PubMed ID: 30257870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Touchscreen learning deficits in Ube3a, Ts65Dn and Mecp2 mouse models of neurodevelopmental disorders with intellectual disabilities.
    Leach PT; Crawley JN
    Genes Brain Behav; 2018 Jul; 17(6):e12452. PubMed ID: 29266714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 1031-1034delTAAC (Leu125Stop): a novel familial UBE3A mutation causing Angelman syndrome in two siblings showing distinct phenotypes.
    De Molfetta GA; Ferreira CA; Vidal DO; Giuliani Lde R; Maldonado MJ; Silva WA
    BMC Med Genet; 2012 Dec; 13():124. PubMed ID: 23256887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angelman syndrome: a journey through the brain.
    Maranga C; Fernandes TG; Bekman E; da Rocha ST
    FEBS J; 2020 Jun; 287(11):2154-2175. PubMed ID: 32087041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Altered ultrasonic vocalization and impaired learning and memory in Angelman syndrome mouse model with a large maternal deletion from Ube3a to Gabrb3.
    Jiang YH; Pan Y; Zhu L; Landa L; Yoo J; Spencer C; Lorenzo I; Brilliant M; Noebels J; Beaudet AL
    PLoS One; 2010 Aug; 5(8):e12278. PubMed ID: 20808828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuronal UBE3A substrates hold therapeutic potential for Angelman syndrome.
    Krzeski JC; Judson MC; Philpot BD
    Curr Opin Neurobiol; 2024 Oct; 88():102899. PubMed ID: 39126903
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ube3a reinstatement identifies distinct developmental windows in a murine Angelman syndrome model.
    Silva-Santos S; van Woerden GM; Bruinsma CF; Mientjes E; Jolfaei MA; Distel B; Kushner SA; Elgersma Y
    J Clin Invest; 2015 May; 125(5):2069-76. PubMed ID: 25866966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiscale spatio-temporal dynamics of UBE3A gene in brain physiology and neurodevelopmental disorders.
    Biagioni M; Baronchelli F; Fossati M
    Neurobiol Dis; 2024 Oct; 201():106669. PubMed ID: 39293689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of Small-Molecule Activators of the Ubiquitin Ligase E6AP/UBE3A and Angelman Syndrome-Derived E6AP/UBE3A Variants.
    Offensperger F; Müller F; Jansen J; Hammler D; Götz KH; Marx A; Sirois CL; Chamberlain SJ; Stengel F; Scheffner M
    Cell Chem Biol; 2020 Dec; 27(12):1510-1520.e6. PubMed ID: 32966807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Delayed loss of UBE3A reduces the expression of Angelman syndrome-associated phenotypes.
    Sonzogni M; Hakonen J; Bernabé Kleijn M; Silva-Santos S; Judson MC; Philpot BD; van Woerden GM; Elgersma Y
    Mol Autism; 2019; 10():23. PubMed ID: 31143434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angelman Syndrome: From Mouse Models to Therapy.
    Rotaru DC; Mientjes EJ; Elgersma Y
    Neuroscience; 2020 Oct; 445():172-189. PubMed ID: 32088294
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene Therapy for Angelman Syndrome: Contemporary Approaches and Future Endeavors.
    Tsagkaris C; Papakosta V; Miranda AV; Zacharopoulou L; Danilchenko V; Matiashova L; Dhar A
    Curr Gene Ther; 2020; 19(6):359-366. PubMed ID: 31914913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generation and Characterization of a Novel Angelman Syndrome Mouse Model with a Full Deletion of the
    Syding LA; Kubik-Zahorodna A; Nickl P; Novosadova V; Kopkanova J; Kasparek P; Prochazka J; Sedlacek R
    Cells; 2022 Sep; 11(18):. PubMed ID: 36139390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Truncation of Ube3a-ATS unsilences paternal Ube3a and ameliorates behavioral defects in the Angelman syndrome mouse model.
    Meng L; Person RE; Huang W; Zhu PJ; Costa-Mattioli M; Beaudet AL
    PLoS Genet; 2013; 9(12):e1004039. PubMed ID: 24385930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ube3a reinstatement mitigates epileptogenesis in Angelman syndrome model mice.
    Gu B; Carstens KE; Judson MC; Dalton KA; Rougié M; Clark EP; Dudek SM; Philpot BD
    J Clin Invest; 2019 Jan; 129(1):163-168. PubMed ID: 30352049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenetic overlap in autism-spectrum neurodevelopmental disorders: MECP2 deficiency causes reduced expression of UBE3A and GABRB3.
    Samaco RC; Hogart A; LaSalle JM
    Hum Mol Genet; 2005 Feb; 14(4):483-92. PubMed ID: 15615769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of cerebellar function in Ube3a-deficient mice reveals novel genotype-specific behaviors.
    Heck DH; Zhao Y; Roy S; LeDoux MS; Reiter LT
    Hum Mol Genet; 2008 Jul; 17(14):2181-9. PubMed ID: 18413322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.